LCG
PCVX icon

Lisanti Capital Growth’s Vaxcyte PCVX Stock Holding History

Lisanti Capital Growth’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,515
Closed -$3.72M – 131
2024
Q3 		$3.72M Buy
32,515
+13,175
+68% +$1.19M 0.94% 42
2024
Q2 		$1.46M Buy
+19,340
New +$1.32M 0.35% 93
2023
Q4 		– Sell
-34,970
Closed -$1.78M – 161
2023
Q3 		$1.78M Sell
34,970
-97,765
-74% -$4.82M 0.28% 107
2023
Q2 		$6.63M Buy
+132,735
New +$6.29M 0.92% 41

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lisanti Capital Growth's PCVX Position: Q4 2024 in Review

Lisanti Capital Growth sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 32,515 shares — an estimated $3.72M sold.

Lisanti Capital Growth first reported a position in PCVX in Q2 2023 and held it in 4 quarters. The position peaked at $6.63M in Q2 2023. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Lisanti Capital Growth reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Lisanti Capital Growth sold 32,515 Vaxcyte shares in Q4 2024, an estimated $3.72M.
  • Lisanti Capital Growth first reported a position in Vaxcyte in Q2 2023 and held it in 4 quarters.
  • Lisanti Capital Growth's Vaxcyte position peaked at $6.63M in Q2 2023.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Lisanti Capital Growth's 13F filing for Q4 2024, filed 7 Feb 2025.